Quantum BioPharma Announces Plans to Voluntarily Delist its Class B Shares from the Canadian Securities Exchange
Quantum BioPharma has applied to voluntarily delist its Class B subordinate voting shares from the Canadian Securities Exchange while maintaining its listings on the Nasdaq Capital Market, Frankfurt Stock Exchange, and Upstream. Management stated that trading volume on the CSE no longer justified the associated expenses and regulatory burdens, and they believe consolidating trading to Nasdaq may benefit long-term liquidity.
Key figures
- Unbuzzd royalty threshold
- 250000000
- Unbuzzd initial royalty rate
- 7%
- Unbuzzd post threshold royalty rate
- 3%
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.